1. Home
  2. HALO vs SNN Comparison

HALO vs SNN Comparison

Compare HALO & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$108.28

Market Cap

11.2B

Sector

Health Care

ML Signal

HOLD

Logo Smith & Nephew SNATS Inc.

SNN

Smith & Nephew SNATS Inc.

HOLD

Current Price

$29.58

Market Cap

12.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HALO
SNN
Founded
1998
1856
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2B
12.3B
IPO Year
2001
2002

Fundamental Metrics

Financial Performance
Metric
HALO
SNN
Price
$108.28
$29.58
Analyst Decision
Buy
Hold
Analyst Count
11
2
Target Price
$78.64
$36.25
AVG Volume (30 Days)
2.3M
1.4M
Earning Date
05-05-2026
03-16-2026
Dividend Yield
N/A
2.48%
EPS Growth
N/A
N/A
EPS
3.11
N/A
Revenue
$151,862,000.00
N/A
Revenue This Year
$28.24
$8.58
Revenue Next Year
$12.56
$5.60
P/E Ratio
$34.78
$64.97
Revenue Growth
N/A
N/A
52 Week Low
$61.23
$28.56
52 Week High
$108.49
$38.79

Technical Indicators

Market Signals
Indicator
HALO
SNN
Relative Strength Index (RSI) 77.65 45.05
Support Level $67.12 $29.24
Resistance Level N/A $31.18
Average True Range (ATR) 3.53 0.43
MACD 0.75 -0.12
Stochastic Oscillator 97.08 51.78

Price Performance

Historical Comparison
HALO
SNN

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About SNN Smith & Nephew SNATS Inc.

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.

Share on Social Networks: